INFU vs ACLX

For growth investors, InfuSystem Holdings, Inc.

(INFU) is the stronger pick with 6. 4% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). InfuSystem Holdings, Inc. (INFU) offers the better valuation at 32. 7x trailing P/E (24. 4x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -50. 9% for InfuSystem Holdings, Inc. (INFU). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus INFU's +206. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 34β versus InfuSystem Holdings, Inc. 's 1. 50β — meaning INFU is approximately -544% more volatile than ACLX relative to the S&P 500. On balance sheet safety, InfuSystem Holdings, Inc. (INFU) carries a lower debt/equity ratio of 6% versus 24% for Arcellx, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), InfuSystem Holdings, Inc.

(INFU) is pulling ahead at 6. 4% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -103. 5% for Arcellx, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InfuSystem Holdings, Inc.

(INFU) is the more profitable company, earning 10. 2% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INFU leads at 8. 3% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for INFU: 47.

9% to $15. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). InfuSystem Holdings, Inc. (INFU) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLX: +584. 9%, INFU: +206. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.